Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib plus Fulvestrant in HR+ Metastatic Breast Cancer
NCT00082810Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2004
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Clinical Benefit Rate at 24 weeks. Started Mar 2004; status: completed.
02
Drugs
tipifarnib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00082810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082810.